Your browser is no longer supported. Please, upgrade your browser.
Settings
NOVN Novan, Inc. daily Stock Chart
NOVN [NASD]
Novan, Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own35.49% Shs Outstand21.58M Perf Week10.00%
Market Cap18.99M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float16.82M Perf Month-36.69%
Income-12.70M PEG- EPS next Q-0.23 Inst Own6.40% Short Float0.34% Perf Quarter-40.94%
Sales6.00M P/S3.17 EPS this Y78.90% Inst Trans1.10% Short Ratio1.34 Perf Half Y-64.87%
Book/sh0.20 P/B4.40 EPS next Y38.00% ROA-35.90% Target Price6.00 Perf Year-72.24%
Cash/sh0.38 P/C2.32 EPS next 5Y- ROE-272.10% 52W Range0.65 - 3.32 Perf YTD6.02%
Dividend- P/FCF- EPS past 5Y-3.60% ROI-216.40% 52W High-72.51% Beta-
Dividend %- Quick Ratio1.00 Sales past 5Y17.20% Gross Margin- 52W Low40.43% ATR0.13
Employees48 Current Ratio1.00 Sales Q/Q566.70% Oper. Margin- RSI (14)47.93 Volatility19.84% 14.30%
OptionableNo Debt/Eq1.54 EPS Q/Q153.60% Profit Margin- Rel Volume0.12 Prev Close0.88
ShortableYes LT Debt/Eq1.54 EarningsMay 14 BMO Payout- Avg Volume42.69K Price0.91
Recom2.00 SMA203.25% SMA50-16.04% SMA200-52.31% Volume1,025 Change3.73%
Apr-09-19 05:19AM  European markets tick higher despite U.S. tariffs threat MarketWatch
Mar-29-19 02:35PM  Novan stock plummets as Durham company searches for additional financing American City Business Journals -7.27%
Mar-19-19 10:30AM  Will NOVAN INC (NOVN) Report Negative Q4 Earnings? What You Should Know Zacks +12.82%
09:00AM  Novan and Sato Advance Japan Market and Dermatology Partnership GlobeNewswire
Mar-11-19 08:00AM  Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates GlobeNewswire +7.41%
Mar-07-19 07:01AM  Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now? Zacks
Mar-05-19 01:17AM  Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®* GlobeNewswire
Mar-04-19 01:16AM  Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China GlobeNewswire
Feb-28-19 07:52AM  Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting GlobeNewswire
Feb-25-19 05:57PM  Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off GlobeNewswire
01:16AM  Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a) GlobeNewswire
Feb-13-19 04:25PM  Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease GlobeNewswire
Feb-12-19 07:41AM  Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now? Zacks
Jan-30-19 04:15PM  Novan Provides Business Update GlobeNewswire
Jan-23-19 02:59PM  Novan faces delisting from Nasdaq American City Business Journals
Jan-11-19 07:02PM  Cramer's Exec Cut: The biggest names in healthand Apple... CNBC Videos -6.19%
Jan-07-19 06:40PM  Novartis CEO on chasing cures over profitable treatments CNBC Videos +6.00%
Jan-02-19 02:33PM  Novan shakes up leadership again American City Business Journals +18.07%
06:15AM  Novan Announces Management Changes and Provides Business Update GlobeNewswire
Dec-28-18 07:22AM  Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now? Zacks
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-20-18 11:25AM  Can We See Significant Insider Ownership On The Novan, Inc. (NASDAQ:NOVN) Share Register? Simply Wall St. -7.48%
Dec-11-18 09:22AM  Novan Announces Top-Line Data From Mid-Stage Molluscum Study Zacks +19.05%
08:00AM  Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit GlobeNewswire
Dec-10-18 07:30AM  Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily GlobeNewswire -9.35%
Dec-06-18 07:32AM  Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now? Zacks -16.14%
Nov-20-18 08:05AM  Novan to Present at Piper Jaffray 30th Annual Healthcare Conference GlobeNewswire -9.79%
Nov-19-18 06:46PM  Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder GlobeNewswire
08:45AM  Consolidated Research: 2018 Summary Expectations for Moleculin Biotech, Novan, PAVmed, Maui Land & Pineapple, Hallmark Financial Services, and McEwen Mining Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-14-18 06:30AM  Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results GlobeNewswire
Nov-12-18 03:20PM  Novan (NOVN) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:05AM  Novan Announces Corporate Update Conference Call and Webcast GlobeNewswire
Nov-05-18 02:29PM  The most valuable public companies in the Triangle (Slideshow) American City Business Journals
Nov-01-18 08:05AM  Novan Publication Supports Womens Health Business Unit Initiative and Nitric Oxides Potential Against HPV-Associated Diseases GlobeNewswire
Oct-25-18 07:05AM  Novan Creates Dedicated Womens Health Business Unit GlobeNewswire
Oct-18-18 12:53AM  European markets open mixed as Brexit talks rumble on CNBC -5.84%
Oct-16-18 08:05AM  Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation GlobeNewswire +11.03%
Oct-08-18 12:12PM  Novan scores $11M with partnership with Japanese pharma American City Business Journals
08:00AM  Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan GlobeNewswire
Oct-01-18 08:05AM  Novans Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November GlobeNewswire
Sep-27-18 01:12PM  Novartis strikes deal with Chinese firm to make Kymriah Reuters
06:30AM  Novan Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-26-18 12:54PM  Before You Buy Novan Incs (NASDAQ:NOVN), Consider This Simply Wall St.
Sep-25-18 08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga -5.67%
Sep-24-18 04:15PM  Novan Receives FDA Guidance for SB204 and Acne Indication GlobeNewswire
Aug-21-18 08:40AM  The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows Benzinga
Aug-20-18 11:44AM  Novan Rallies On Positive Early Results For Inflammatory Skin Disease Medication Benzinga
06:30AM  Novan Announces Promising Clinical Results with SB414 GlobeNewswire
Aug-08-18 12:45PM  New Novan incentive plan targets share price goals and $25M, $50M bonus pools American City Business Journals
08:25AM  Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract GlobeNewswire
Jul-16-18 07:06AM  Novartis had longer and more detailed relationship with Trump lawyer Michael Cohen, Senate report finds MarketWatch
Jun-13-18 08:05AM  Novan to Participate in Upcoming Investor Conferences GlobeNewswire
Jun-07-18 01:54PM  Does Novan Incs (NASDAQ:NOVN) Earnings Growth Make It An Outperformer? Simply Wall St.
Jun-01-18 08:05AM  Novan Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-17-18 08:05AM  SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment GlobeNewswire
May-15-18 08:10AM  Novan Provides Update on SB414 Inflammatory Skin Disease Development Program GlobeNewswire
May-08-18 08:40PM  Trump attorney Cohen got about $500,000 from Russian oligarch, Stormy Daniels' lawyer claims CNBC
Apr-13-18 08:10AM  Same as the old boss Novan makes interim CEO permanent American City Business Journals
Apr-12-18 07:05AM  Novan Advances Organization and Strengthens Leadership Team GlobeNewswire
Apr-10-18 04:07PM  Novan Inc (NASDAQ:NOVN): Poised For Long-Term Success? Simply Wall St.
Apr-09-18 07:20PM  Cramer: There's always a better time to sell CNBC Videos
06:31PM  Cramer: We got too negative on Fridaythere's always a be... CNBC Videos
Mar-29-18 08:05AM  Novan Announces Corporate Update Conference Call and Webcast GlobeNewswire
Mar-26-18 10:19PM  Novartis CEO on Alcon and Sandoz CNBC Videos -8.04%
Mar-25-18 04:54AM  Here's what CEOs and other leaders are saying at the China Development Forum in Beijing CNBC
Mar-07-18 01:16AM  Novartis expands alliance with Science 37 to advance virtual clinical trials program GlobeNewswire
Mar-06-18 01:17AM  Novartis' Xolair® recommended in new global chronic urticaria guideline GlobeNewswire
Mar-02-18 07:24AM  Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting GlobeNewswire
Mar-01-18 01:16AM  Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis GlobeNewswire
Feb-22-18 01:16AM  Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation GlobeNewswire
Feb-21-18 08:00AM  Dr. Eugene Sun Appointed to Novan Board of Directors GlobeNewswire
Feb-16-18 04:06PM  Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis GlobeNewswire
04:06PM  Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis GlobeNewswire
Feb-14-18 01:16AM  Novartis forms alliance to develop medicines for treating infectious diarrheal disease GlobeNewswire +5.86%
Feb-13-18 08:05AM  Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne GlobeNewswire +6.93%
01:17AM  Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis GlobeNewswire
Feb-08-18 01:16AM  Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis GlobeNewswire
Jan-31-18 05:01PM  Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL GlobeNewswire
Jan-30-18 03:45PM  SAS founder Goodnight's investment firm becomes Novan's largest stockholder American City Business Journals
Jan-25-18 02:10PM  2 Novan execs out as company pushes to broaden focus American City Business Journals
09:00AM  Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206 GlobeNewswire
Jan-24-18 04:02PM  Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss GlobeNewswire
02:48PM  Trading GE after earnings. Plus, the trade on Kroger & No... CNBC Videos
01:03PM  NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017 GlobeNewswire
01:02AM  Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase GlobeNewswire
Jan-22-18 04:36PM  Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments GlobeNewswire
Jan-18-18 05:31AM  Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars GlobeNewswire
Jan-17-18 01:16AM  Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL GlobeNewswire
Jan-16-18 01:16AM  Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients GlobeNewswire
01:02AM  Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA GlobeNewswire
Jan-11-18 09:15AM  Novan Announces Closing of Offering of Common Stock and Warrants GlobeNewswire
09:10AM  Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference GlobeNewswire
01:01AM  Novartis appoints Elizabeth Barrett as Oncology Head GlobeNewswire
Jan-09-18 01:16AM  Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab** GlobeNewswire
Jan-05-18 12:40PM  Novan looks to raise $38M in public offering American City Business Journals -20.75%
09:00AM  Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants GlobeNewswire
Jan-04-18 04:07PM  Novan Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
01:16AM  Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA) GlobeNewswire
Jan-03-18 01:16AM  Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer GlobeNewswire
Jan-02-18 10:46AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018 ACCESSWIRE
Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. has a strategic alliance with Orion Corporation to manufacture topical nitric oxide-releasing product candidates. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INGRAM ROBERT ALEXANDERDirectorSep 28Buy2.8450,000142,000119,777Oct 01 04:34 PM
Martin G. KellyChief Executive OfficerSep 26Buy2.7310,00027,30040,000Sep 27 04:24 PM
HUNTER JEFF NEVP & Chief Business OfficerAug 22Option Exercise1.1211,66713,067186,666Aug 24 08:41 AM
PALMOUR JOHN WDirectorAug 22Buy2.6620,00053,200273,568Aug 24 08:43 AM
Martin G. KellyChief Executive OfficerAug 21Buy2.7130,00081,30030,000Aug 23 04:32 PM